Life sciences and biotechnology company Enzo Biochem (Farmingdale, N.Y.) has paid $18 million in cash and stock to acquire privately held Biomol International (Plymouth Meeting, Pa., and Exeter, England). With annual revenues of approximately $12 million and 50 employees in its United States and United Kingdom facilities, Biomol produces specialty life science products in the areas of signal transduction, lipid research, apoptosis, neuroscience, and drug discovery, with a research focus in functional proteomics.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

June 2008 - Table of Contents

DTTR June 2008 (full PDF issue)

SACGHS Report Calls for Expanded FDA Oversight

Myriad Genetics to Expand Direct-to-Consumer Marketing Efforts

FDA Clears Third Warfarin Genotyping Test

Congress Passes Ban on Genetic Discrimination, Measure Ready for Signing

Genzyme Genetics Launches Testing for Spinal Muscular Atrophy

Inverness Completes Acquisition of Matria Healthcare

SACGHS Calls for Expanded Regulation, Resources for Genetic Testing

Part B Lab Spending Climbs to $6.8 Billion in 2007

LabCorp Expands Companion Diagnostic Development Focus

Beckman Coulter Licenses HCV Test from Siemens

Group B Strep Increases Among Adults

NEJM Study Finds Genetic Links to Neuroblastoma

Saliva-Based Method Shows Promise for Early Diagnosis of Heart Attack

Enzo Biochem Buys Biomol to Boost Life Sciences Business

IVD Stocks Lose 4%; Affymetrix Drops 34%

Outreach Testing by the Numbers